Table 3 Perioperative outcomes reported in studies on preoperative chemotherapy with and without bevacizumab for CLM

Aussilhou

BEV-

50

15

5

5

BEV+

55

18

9

0

Constantinidou

BEV-

650 (100–2200)

54

13

12

13

0

10 (4–32)

2

BEV+

540 (50–2000)

48

12

14

10

5

10 (4–57)

0

D’Angelica

BEV-

-

500 (200–5000)

38

9

6

7 (n.r.)

0

BEV+

235 (85–500)

300 (0–1500)

41

6

19

0

Kesmodel

BEV-

134 (69–408)

200 (50–1750)

43

25

7

2

2

BEV+

139 (67–675)

250 (50–1950)

49

28

1

4

1

Lubezky

BEV-

47

9

2

5

9

4

0

BEV+

35

11

2

1

8

5

2

Mahfud

BEV-

270 (237–302)

658 (407–908)

40

18

9

20

9

13 (8–18)

4

BEV+

248 (224–270)

523 (399–646)

56

31

11

7

7

15 (11–20)

0

Millet

BEV-

300 (175–645)

500 (50–1700)

34

10

12

8 (5–21)

0

BEV+

300 (156–540)

500 (150–1100)

56

12

22

9 (6–22)

0

Pessaux

BEV-

277 (±55)

548 (±233)

19

0

0

0

13.7 (±4.2)

0

BEV+

321 (±160)

983 (±1476)

29

14

0

0

12.7 (±6.3)

0

Reddy

BEV-

600 (350–800)

39

25

7

26

5

7 (6–9)

4

BEV+

425 (263–600)

44

28

10

18

3

8 (7–10)

3

Rong

BEV-

29

1

4

7

1

10 (±50)

BEV+

26

6

1

3

0

9 (±35)

Tamandl

BEV-

34

7

9 (5–47)

0

BEV+

44

11

8 (4–77)

0

Van der Pool

BEV-

32

6

4

7 (3–23)

0

BEV+

25

8

2

6 (3–54)

0

Wicherts

BEV-

341 (±110)

36

5

14

2

3

1

11.3 (±7.1)

0

BEV+

414 (±146)

43

16

8

2

6

2

13.6 (±14.4)

0

Zorzi

BEV-

54

39

31

8

BEV+

42

16

26

5